As part of the agreement, for each year of active sponsorship, Bristol-Myers Squibb can nominate up to three innovative life-sciences and biotech startup companies per year to take up residence in BioLabs' facilities at 180 Varick Street in Manhattan.
The nomination process will launch in early 2018.
A Golden Ticket represents one underwritten bench space per year for one scientist at BioLabs, and a priority spot on the waiting list. The Golden Ticket also promotes collaboration among sponsors and the start-up companies.
The program provides sponsors with early access to potentially transformational targets and technology, and the start-ups with the mentorship of their sponsor teams.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV).
BioLabs is a membership-based network of shared lab facilities located in key biotech innovation clusters in the US, designed exclusively for high-potential, early-stage life science companies. It offers coworking environments that pair premium, fully equipped and supported lab and office space with access to capital and industry partners. Companies can start with a single bench, and scale up as they grow.
BioLabs' founding site is in Kendall Square, Cambridge, Massachusetts, with additional locations in North Carolina; San Diego, California; and opening in New York, New York. Partner sites include LabCentral in Kendall Square, and QB3@953 in San Francisco, California.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results